Summary of Study ST001662
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001067. The data can be accessed directly via it's Project DOI: 10.21228/M8S69H This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001662 |
| Study Title | LC-MS Metabolomics of Urine Reveals Distinct Profiles for Low- and High-Grade Bladder Cancer |
| Study Summary | Bladder cancer (BC) is among the most frequent malignancies worldwide. Novel non-invasive markers are needed to diagnose and stage BC with more accuracy than invasive procedures such as cystoscopy. Our aim was to discover novel urine metabolomic profiles to diagnose and stage non-muscle invasive (NMIBC) and muscle-invasive (MIBC) patients using ultra-performance liquid chromatography analysis (UPLC)-based metabolomics. We prospectively recruited 64 BC patients (19 TaG1, 11 TaG3, 20 T1G3, 12 T2G3, 1 T2G2, 1 T3G3) and 20 age- and sex-matched healthy volunteers without evidence of renal or bladder condition confirmed by ultrasound, from whom we collected a first morning urine sample (before surgery in patients). We conducted a UPLC-quadrupole-time-of-flight mass spectrometry (UPLC-Q-ToF MS) untargeted metabolomic analysis in all urine samples. We selected the discriminant variables between groups with a supervised orthogonal-least-squares discriminant analysis (OPLS-DA) analysis and we identified them by querying their exact mass against those presented in online databases through a mediator platform. Subsequently, we confirmed the dysregulated metabolites when chemical standards were commercially available. We compared all clinical groups of patients with controls and we identified dysregulated metabolites in every comparison. Of these, we confirmed p-cresol glucuronide as potential diagnostic biomarker, and potential staging tool for NMIBC patients. Among NMIBC patients, we identified p-coumaric acid as a potential staging biomarker for milder NMIBC stages (TaG1). Additionally, we confirmed spermine and adenosine as potential staging biomarkers for MIBC. This is the first study conducted in urine samples of most stages of NMIBC and MIBC and healthy controls to identify non-invasive biomarkers. Once confirmed, these may improve BC management thus reducing the use of current harmful diagnostic techniques. |
| Institute | Health Research Institute Hospital La Fe |
| Laboratory | Analytical Unit |
| Last Name | Roca Marugán |
| First Name | Marta |
| Address | Avenida Fernando Abril Martorell 106, Torre A, Valencia, Valencia, 46026, Spain |
| marta_roca@iislafe.es | |
| Phone | 680888576 |
| Submit Date | 2021-01-21 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzXML |
| Analysis Type Detail | GC-MS |
| Release Date | 2021-08-16 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO001732 |
| Collection Summary: | Study subjects Sixty-four BC patients were recruited between May 2016 and April 2018 at La Fe University and Polytechnic Hospital (Valencia, Spain). Twenty age- and sex-matched healthy volunteers (control group) who underwent an ultrasound scan to rule out the presence of urological malignancies or other alterations were also recruited. Patients and controls were clinically followed-up until May 2020. Pre-operative clinical staging was performed through physical examination, urine cytology and CT scans of the chest, abdomen and pelvis (in case of invasive bladder cancer). The tumor histological classification was done according to grade in the WHO 1973 and 2004 classifications. Demographic and clinical data were collected. The exclusion criteria were lack of informed consent, absence of histological confirmation and presence of other malignancies. Informed consent was obtained from all participants according to protocols approved by the ethics review board at La Fe University and Polytechnic Hospital. The study was performed according to the declaration of Helsinki, as amended in Edinburgh in 2000. Urine collection A first morning urine sample of 25-50 ml was collected in sterile containers from all participants. Urine was kept at 4 ºC until processing and centrifuged at 805 x g for 5 min at 4 ºC to remove cellular debris. Supernatant was aliquoted and frozen at -80 ºC until analyzed. The concentration of creatinine in each urine sample was measured by clinical laboratory standardized methods. |
| Sample Type: | Urine |
